TABLE 1

Demographic characteristics and predose laboratory summary statistics for study subjects in each treatment groupa

Characteristic or statisticValue for treatment group
TQ + DHA-PQP (n = 24)TQ + AL (n = 24)DHA-PQP (n = 24)AL (n = 24)TQ (n = 24)
Mean age (yr) (SD)40.0 (11.8)39.5 (10.4)38.3 (11.2)35.8 (13.4)35.8 (10.7)
Mean wt (kg) (SD)78.6 (12.0)78.3 (9.5)76.8 (10.4)76.0 (12.1)76.3 (11.5)
Mean ht (cm) (SD)174.5 (9.8)173.9 (8.5)176.5 (8.7)172.6 (10.0)173.6 (9.2)
No. of male subjects/no. of female subjects19/519/521/317/718/6
No. (%) of subjects of race
    Caucasian5 (21)8 (33)7 (29)5 (21)2 (8)
    Black or African American18 (75)13 (54)16 (67)19 (79)21 (88)
    Other1 (4)3 (12)1 (4)01 (4)
Mean G6DP enzyme activity (U/g Hb) (SD)10.6 (1.6)10.4 (1.5)10.0 (1.1)9.9 (1.1)10.2 (1.0)
Mean hemoglobin level (g/dl) (SD)13.8 (1.1)13.8 (1.4)14.1 (1.0)13.8 (1.5)13.8 (1.3)
Mean methemoglobin level (%) (SD)0.99 (0.33)1.00 (0.28)0.95 (0.30)0.98 (0.37)1.13 (0.32)
Mean creatinine level (μmol/dl) (SD)8.2 (1.7)8.5 (1.8)8.5 (1.4)8.1 (1.5)8.4 (1.5)
Mean albumin level (g/dl) (SD)3.8 (0.3)3.8 (0.3)3.8 (0.2)3.8 (0.3)3.8 (0.3)
Mean ALT level (U/liter) (SD)25.8 (8.9)25.3 (11.8)23.6 (9.4)22.8 (8.3)21.5 (7.6)
Mean AST level (U/liter)20.1 (7.7)17.3 (4.7)17.1 (3.5)23.1 (28.0)18.3 (4.3)
  • a TQ, tafenoquine; DHA-PQP, dihydroartemisinin-piperaquine; AL, artemether-lumefantrine; ALT, alanine aminotransferase; AST, aspartate aminotransferase; Hb, hemoglobin.